MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
PSNL Personalis
- 5.750
- +0.490+9.32%
Close Dec 20 16:00 ET
- 5.950
- +0.200+3.48%
Post 16:26 ET
406.23MMarket Cap-3.32P/E (TTM)
7.190High5.600Low8.02MVolume5.690Open5.260Pre Close52.14MTurnover17.97%Turnover RatioLossP/E (Static)70.65MShares7.20052wk High2.44P/B256.59MFloat Cap1.12052wk Low--Dividend TTM44.62MShs Float53.460Historical High--Div YieldTTM30.22%Amplitude0.891Historical Low6.503Avg Price1Lot Size
Personalis News
Needham Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $7.25
H.C. Wainwright Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $11
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Strategic Partnerships and Investments Drive Personalis's Growth and Reaffirm Buy Rating
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday
Personalis Price Target Maintained With a $7.25/Share by Needham
Personalis Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Personalis, Raises Price Target to $11
Personalis Analyst Ratings
Express News | Personalis Inc : Btig Raises Target Price to $8 From $7
Stock Of The Day: Where Does The Merck Downtrend End?
Personalis Rallies Following $50 Million Investment From Merck, Extended Agreement With Moderna
Merck Buys $50 Million of Personalis Stock
Personalis Signs Multi-Year Extension With Moderna To Utilize Its ImmunoID NeXT Platform And Technology For V940/mRNA-4157
Express News | Personalis Inc: Merck Has Agreed to Purchase $50 Mln of Personalis Common Stock in a Private Placement at a Price of $3.56 per Share
Express News | Personalis Advances Business Strategy With Investment From Merck and Extends Collaboration With Moderna
Tempus AI, Inc (TEM) Expands Partnership With Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7
Personalis (PSNL) Gets a Buy From Lake Street
Personalis And Tempus Expand Collaboration, Enabling Tempus To Offer Personalis' NeXT Personal MRD Product To Pharmaceutical And Biotech Customers
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
